Dr. Clay Siegall founded and is the CEO at Seattle Genetics, a biotech company which specializes in developing targeted therapeutic medicines for condition types which have yet to see substantial improvements in mortality rates.
Since he founded Seattle Genetic , Siegall has guided the company to become the leading firm in the industry of targeted therapy, producing the very first FDA-regulated antibody drug company, that now holds various approved indications, in addition to developing a strong portfolio of over 20 medications and a series of strategic partnerships with drugmakers including Pfizer, Genentech, Bayer as well as many others.
Under Siegall’s direction, Seattle Genetics went from a small startup having just a tiny research team to a truly dynamic player in cancer research. Siegall has great ideas for the Seattle Genetics future. Boasting an expanding inventory of medications in development stage and a quickly expanding variety of potential implications for their current drug list, Seattle Genetics is equipped to advance into the next age of medication development with power.
Siegall thinks the old style of cancer treatments, specifically systemic chemotherapy, is nearing its expiration date. As the cost and efficiency of targeted therapy is further developed in the near future, he believes the treatments of the past are going to be replaced by targeted drugs which are more effective.
Dr. Siegalls interest in the industry began with his lifelong interest in medicine, the potential of technology and innovation to overcome illness, to interrupt nature and return to wellness to people whose fates would otherwise give them death. Seigall initially got interested in cancer treatment while he was studying zoology at University of Maryland. A member of his family fell ill and the therapy method was very harsh. So much, In fact, they managed to develop extreme anemia, coming close to death not from cancer, but chemotherapy.